The Novel Biomarker of Germ Cell Tumours, Micro-RNA-371a-3p, Has a Very Rapid Decay in Patients with Clinical Stage 1
- PMID: 29698973
- PMCID: PMC6039090
- DOI: 10.1159/000488771
The Novel Biomarker of Germ Cell Tumours, Micro-RNA-371a-3p, Has a Very Rapid Decay in Patients with Clinical Stage 1
Abstract
Background: Accumulating evidence suggests serum levels of microRNA (miR)-371a-3p to be a novel tumour marker of testicular germ cell tumours (GCTs). Presently, there is only limited information regarding the velocity of decline of serum levels in response to treatment.
Patients and methods: Twenty-four patients with testicular GCT (20 seminoma, 4 nonseminoma, median age 40 years) with clinical stage 1 had measurements of serum levels of miR-371a-3p preoperatively and repeatedly on the following 3 days. Three had additional tests done within 24 h after surgery. Measurement results were analysed using descriptive statistical methods.
Results: Serum levels dropped to 2.62, 1.27, and 0.47% of the preoperative level within 1, 2, and 3 days, respectively. The computed half-life amounts to 3.7-7 h. The velocity of decay is significantly associated with tumour size.
Conclusions: Serum-levels of miR-371a-3p have a short half-life of less than 12 h. The rapid decay after treatment represents a valuable feature confirming the usefulness of miR-371a-3p as a valuable serum biomarker of GCT.
Keywords: Germ cell tumour; MicroRNA-371a-3p; Nonseminoma; Seminoma; Serum biomarker.
© 2018 S. Karger AG, Basel.
Figures



Similar articles
-
MicroRNA miR-371a-3p in serum of patients with germ cell tumours: evaluations for establishing a serum biomarker.Andrology. 2015 Jan;3(1):78-84. doi: 10.1111/j.2047-2927.2014.00269.x. Epub 2014 Sep 4. Andrology. 2015. PMID: 25187505
-
Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study.J Clin Oncol. 2019 Jun 1;37(16):1412-1423. doi: 10.1200/JCO.18.01480. Epub 2019 Mar 15. J Clin Oncol. 2019. PMID: 30875280 Free PMC article.
-
Can germ cell neoplasia in situ be diagnosed by measuring serum levels of microRNA371a-3p?J Cancer Res Clin Oncol. 2017 Nov;143(11):2383-2392. doi: 10.1007/s00432-017-2490-7. Epub 2017 Aug 17. J Cancer Res Clin Oncol. 2017. PMID: 28819887 Free PMC article.
-
[Testicular Germ Cell Tumours - features and prospects of the novel tumour marker microRNA-371a-3p (M371 test): a narrative review].Aktuelle Urol. 2024 Dec;55(6):510-519. doi: 10.1055/a-2358-8355. Epub 2024 Aug 12. Aktuelle Urol. 2024. PMID: 39134037 Review. German.
-
Circulating MicroRNAs, the Next-Generation Serum Biomarkers in Testicular Germ Cell Tumours: A Systematic Review.Eur Urol. 2021 Oct;80(4):456-466. doi: 10.1016/j.eururo.2021.06.006. Epub 2021 Jun 24. Eur Urol. 2021. PMID: 34175151
Cited by
-
Testicular cancer.Nat Rev Dis Primers. 2018 Oct 5;4(1):29. doi: 10.1038/s41572-018-0029-0. Nat Rev Dis Primers. 2018. PMID: 30291251 Review.
-
Identification and Validation Model for Informative Liquid Biopsy-Based microRNA Biomarkers: Insights from Germ Cell Tumor In Vitro, In Vivo and Patient-Derived Data.Cells. 2019 Dec 14;8(12):1637. doi: 10.3390/cells8121637. Cells. 2019. PMID: 31847394 Free PMC article.
-
Graded expression of microRNA-371a-3p in tumor tissues, contralateral testes, and in serum of patients with testicular germ cell tumor.Oncotarget. 2020 Apr 21;11(16):1462-1473. doi: 10.18632/oncotarget.27565. eCollection 2020 Apr 21. Oncotarget. 2020. PMID: 32363003 Free PMC article.
-
Current and Evolving Biomarkers in the Diagnosis and Management of Testicular Germ Cell Tumors.J Clin Med. 2024 Dec 6;13(23):7448. doi: 10.3390/jcm13237448. J Clin Med. 2024. PMID: 39685906 Free PMC article. Review.
-
Circulating microRNAs as biomarkers to assist the management of the malignant germ-cell-tumour subtype choriocarcinoma.Transl Oncol. 2021 Jan;14(1):100904. doi: 10.1016/j.tranon.2020.100904. Epub 2020 Oct 10. Transl Oncol. 2021. PMID: 33049521 Free PMC article.
References
-
- Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, Horwich A, Laguna MP, Nicolai N, Oldenburg J. Guidelines on testicular cancer: 2015 update. Eur Urol. 2015;68:1054–1068. - PubMed
-
- Murray MJ, Huddart RA, Coleman N. The present and future of serum diagnostic tests for testicular germ cell tumours. Nat Rev Urol. 2016;13:715–725. - PubMed
-
- Neumann A, Keller T, Jocham D, Doehn C. [Human placental alkaline phosphatase (hPLAP) is the most frequently elevated serum marker in testicular cancer] Aktuelle Urol. 2011;42:311–315. - PubMed
-
- Molina Saera J, Aparicio Urtasun J, Díaz Beveridge R, Palomar Abad L, Giménez Ortiz A, Ponce Lorenzo J, Montalar Salcedo J. Epidemiological pattern and time trends in testicular germ-cell tumors: a single institution 20-year experience. Clin Transl Oncol. 2006;8:588–593. - PubMed
-
- Murray MJ, Coleman N. Testicular cancer: a new generation of biomarkers for malignant germ cell tumours. Nat Rev Urol. 2012;9:298–300. - PubMed
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases